WASHINGTON – As the clock ticks down on the May 31 expiration of the Small Business Innovation Research (SBIR) program, the Senate is considering yet another continuing resolution to keep the program running while Congress tries to hammer out the details of a multiyear reauthorization. Read More
The story of Australian firm Bionomics Ltd.'s recent A$14.25 million (US$15.1 million) fundraising offers a good example of how a company can capitalize on strong – even if early stage – data. Read More
Ziopharm Oncology Inc., of New York, submitted an investigational new drug application for Ad-RTS-IL-12, a DNA-based therapeutic. The planned Phase I study will evaluate safety in additional to immunological and biological effects in patients with melanoma. Read More
In 2009, researchers made headlines with the assertion that xenotropic murine leukemia virus-related virus (XMRV) might be a viral infection underlying chronic fatigues syndrome (CFS). Read More
In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry. Read More
One of the supposed advantages of induced pluripotent stem cells (iPS) – reprogrammed cells with embryonic stem cell-like versatility – is that they can be made from a patient's own skin cells, and so should not provoke an immune response when they are transplanted back into a patient after reprogramming. Read More
